IC7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables FranchiseICU Medical's core revenue comes from single-use infusion and vascular consumables that hospitals repurchase per patient episode. That recurring demand and potential platform standardization create predictable, durable revenue streams and high customer stickiness, supporting long-term cash generation.
Infusion Systems Momentum And Regulatory ClearancesRecord pump placements increase the installed base that drives ongoing consumable attachments and higher-margin system sales. Ongoing 510(k) activity and LifeShield software approval demonstrate a functioning R&D/regulatory engine, reinforcing product pipeline durability and future attach-rate revenue.
Positive Cash Generation And Improving Balance-sheet MetricsSustained positive operating and free cash flow provides financial flexibility to fund R&D, integration costs, and deleveraging. The decline in leverage versus 2024 and explicit management targets to reduce net debt support structural balance-sheet improvement and lower solvency risk over the medium term.
Bears Say
Revenue Decline And Historical VolatilityTrailing revenue contraction and past multi-year swings (loss years 2022–2024) make top-line forecasting uncertain. Persistent or episodic declines reduce the base for margin expansion and constrain the company's ability to convert scale into durable profit improvement over the next several quarters.
Thin Profitability And Low ReturnsNet margins and ROE remain well below historical peaks, indicating limited current ability to convert revenue into sustainable shareholder returns. Thin profitability reduces reinvestment capacity and prolongs the period required to materially improve returns even if top-line trends stabilize.
FDA Testing/timing Risk For New Pump HardwareExtended regulatory testing delays can push out revenue recognition for new pump hardware and delay higher-margin attachable disposables. Timing risk from larger FDA requirements creates structural uncertainty for the growth trajectory of Infusion Systems and complicates planning for leverage reduction.
ICU Medical News
IC7 FAQ
What was Icu Medical’s price range in the past 12 months?
Currently, no data Available
What is Icu Medical’s market cap?
Icu Medical’s market cap is CHF3.41B.
When is Icu Medical’s upcoming earnings report date?
Icu Medical’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Icu Medical’s earnings last quarter?
Currently, no data Available
Is Icu Medical overvalued?
According to Wall Street analysts Icu Medical’s price is currently Undervalued.
Does Icu Medical pay dividends?
Icu Medical does not currently pay dividends.
What is Icu Medical’s EPS estimate?
Icu Medical’s EPS estimate is 1.54.
How many shares outstanding does Icu Medical have?
Currently, no data Available
What happened to Icu Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Icu Medical?
Currently, no hedge funds are holding shares in CH:IC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ICU Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF135.21 (― Upside)
CHF135.21 (― Upside)
Insider Transactions
Sold Shares
Worth CHF712.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.08%
Trailing 12-Months
Company Description
Icu Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
IC7 Company Deck
IC7 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call framed a company with healthy operational momentum in its core businesses: record Infusion Systems results, modest consumables growth, gross margin expansion, and EPS improvement (+15%). Offsetting these positives are transitory but material items that affect reported results and near-term risk: the IV Solutions deconsolidation lowering reported revenue, tariff and logistics cost pressures (potential ~$10M headwind), ongoing integration/remediation spend, and timing risk from additional FDA testing for new pump hardware. Management reiterated full-year guidance and articulated paths to offset macro and trade headwinds through tariff benefits and operational efficiencies, signaling confidence in achieving targets.View all CH:IC7 earnings summaries